Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index; 29 of the 76 sources its claims cite were checked for support.
Abstract
© 2020 S. Karger AG, Basel. This is the peer-reviewed but unedited manuscript version of the following article: Schifano F: Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs. Psychother Psychosom 2020;89:274-282. DOI: 10.1159/000361001. The final, published version is available at https://doi.org/10.1159/000507897.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 Valid · 20 Not valid · 37 Not checked · 8 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Although there are a few hundreds of exotic BDZ discussed within the NPS community (28), a non-participant, multilingual, qualitative/netnographic study recently focused on those 29 exotic BDZ which have been formally identified as NPS by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (26).”
§ Coming off prescribed psychotropic medications: insights from their use as recreational drugs > GABAergics (benzodiazepines; 'Z-drugs'; GABA-A/GABA-B agonists)
What the sources say
- Disputedcites [26] Schifano F, Chiappini S, Corkery JM, Guirguis A. An Insight into Z- Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. Int J Neuropsychopharmacol. 2019 Apr 1;22(4):270-277. sourceExperimental — accuracy not yet measured
The cited work is not a netnographic study of exotic benzodiazepines: its Abstract (Background) and Significance Statement describe it as an analysis of suspected-adverse-drug-reaction datasets that the European Medicines Agency collects through EudraVigilance, covering only the three approved Z-drugs (zaleplon, zopiclone, zolpidem), and its Methods detail a formal EMA request for Individual Case Safety Reports under MedDRA Preferred Terms ('drug abuse', 'intentional product misuse', 'drug dependence', 'withdrawal syndrome') with 33 240 ADRs / some 6 246 unique cases (Discussion). Our copy contains no passage describing a non-participant, multilingual, qualitative/netnographic design, no mention of EMCDDA, and no count of 29 exotic benzodiazepines; the only NPS reference is a passing citation to Schifano et al. (2018) for rising novel-psychoactive-substance misuse (Discussion), which does not credit this paper with the netnographic study. Thus the paper's own self-description contradicts the design and subject matter attributed to it. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Hence, withdrawal symptoms that occur upon discontinuation of medications prescribed for valid medical reasons do not suggest, per se, either a substance-related (13) or an addiction disorder (6).”
§ Coming off prescribed psychotropic medications: insights from their use as recreational drugs > Recreational and prescribing psychotropics; terminology issues
What the sources say
- Partly supportedcites [13] Fava GA, Rafanelli C. Iatrogenic Factors in Psychopathology. Psychother Psychosom. 2019;88(3):129-140. sourceExperimental — accuracy not yet measured
Our copy of Fava & Rafanelli (2019) supports the first half of the attribution: in 'The Concept of Behavioral Toxicity' it states that withdrawal symptoms following discontinuation of prescribed psychotropic drugs (benzodiazepines, antipsychotics, antidepressants) are a form of iatrogenic behavioral toxicity, and in 'The Renaissance of Psychopathology' / 'Cascade Iatrogenesis' it stresses that such symptoms are easily misread as signs of relapse rather than as drug-related events. But no passage addresses substance-related or addiction disorders at all: searches for 'substance use disorder', 'addiction', 'dependence/craving/misuse' returned only the reference list (e.g. Nielsen et al. on dependence vs. withdrawal) and one mention of dependence arising in cascade iatrogenesis, never the diagnostic point that withdrawal per se does not indicate a substance-related or addiction disorder. That specific claim is therefore not stated in this source. (LLM, conf=0.65)
- Not checked yetcites [6] Heinz A, Daedelow LS, Wackerhagen C, Di Chiara G. Addiction Theory matters-Why There Is No Dependence on Caffeine or Antidepressant Medication. Addict Biol. 2020 Mar;25(2):e12735. source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Within both online drug forum communities and social networks, there are some educated/informed users (the 'psychonauts'; 24) who are keen to 'test' a range of molecules, including prescribing psychotropics, to achieve specific mindsets.”
§ Coming off prescribed psychotropic medications: insights from their use as recreational drugs > High-dosage medications' misuse/abuse; the psychonauts' world
What the sources say
- Could not verifycites [24] Franc A, Kubová K, Elbl J, Muselík J, Vetchý D, Šaloun J, et al. Diazepam filled hard capsules intended for detoxification of patients addicted to benzodiazepines and Z-drugs. Eur J Hosp Pharm 2019 Jan;26(1):10-15 sourceExperimental — accuracy not yet measured
The Introduction discusses benzodiazepine and Z-drug use, while the Discussion concerns preparation of diazepam capsules. Searches for psychonauts, online drug forums, and testing psychotropics to achieve particular mindsets found no passage addressing the claim in our copy. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Could not verify
None of the sources cited for this claim have been checked yet.
In the paper
“Recreational, abused drugs (e.g.cannabinoids; cocaine; MDMA/ecstasy) appear to increase dopaminergic signalling in ventral striatal regions, including the nucleus accumbens, a key site of the mesolimbic reward pathway (4; 5).”
§ Coming off prescribed psychotropic medications: insights from their use as recreational drugs > Recreational and prescribing psychotropics; terminology issues
What the sources say
- Could not verifycites [4] Balon R, Silberman EK, Starcevic V, Cosci F, Freire RC, Nardi AE, et al. Benzodiazepines, antidepressants and addiction: A plea for conceptual rigor and consistency. J Psychopharmacol. 2019 Nov;33(11):1467-1470. sourceExperimental — accuracy not yet measured
Our copy of Balon et al. (2019) is a short conceptual editorial and contains no passage on dopaminergic signalling, ventral striatum, nucleus accumbens, or the named recreational drugs (searched: 'dopamine nucleus accumbens ventral striatum reward pathway', 'cocaine cannabinoids MDMA ecstasy dopaminergic signalling increase', 'mesolimbic reward system reinforcement euphoria self-administration cocaine'). The only related text is the quoted DSM-5 sentence that drugs of abuse 'directly activate the reward pathways' and produce intense activation of the reward system (What is addiction and what makes a substance addictive?, p. 1), which the authors invoke generically to argue that benzodiazepines get swept into the DSM-5 addictive category — it neither names dopamine, the ventral striatum/nucleus accumbens, nor cannabinoids, cocaine or MDMA. Nothing in our copy contradicts the claim, so this is unverifiable rather than disputed. (LLM, conf=0.72)
- Not checked yetcites [5] Felicetti P, Trotta F, Bonetto C, Santuccio C, Brauchli Pernus Y, Burgner D, et al. Vasculitis Working Group: Spontaneous reports of vasculitis as an adverse event following immunization: a descriptive analysis across three international databases. Vaccine. 2016 Dec 12;34(51):6634- 6640. source
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“All these actions are likely contributing to both its significant psychoactive effects and addictive liability issues (43-44; Table 1).”
§ Coming off prescribed psychotropic medications: insights from their use as recreational drugs > Ketamine and related drugs
What the sources say
- Could not verifycites [43] Chiappini S, Schifano F. A decade of gabapentinoid misuse: an analysis of the European Medicines Agency/EMA 'suspected adverse drug reactions' database. CNS Drugs. 2016 Jul;30(7):647-54. sourceExperimental — accuracy not yet measured
Our copy of the Chiappini & Schifano (2016) gabapentinoid paper does not address ketamine pharmacology. The only mention of ketamine anywhere in the text is in Section 3.4 (Related Fatalities), where it is listed as one of the recreational substances (with alcohol, amphetamines and cannabis) occasionally identified alongside pregabalin/gabapentin fatality reports — nothing about its mechanisms, psychoactive effects or addictive liability. The paper's mechanistic passage (Introduction, section 1) attributes binding to the α2-δ subunit of voltage-gated calcium channels, GABA increase and inhibition of excitatory neurotransmitter release to gabapentinoids, and states it 'remains to be confirmed if gabapentinoid ingestion is associated with meaningful levels of dopamine reward pathway activation'. Searches for 'ketamine', 'NMDA', 'psychoactive effects/addictive liability' returned only gabapentinoid content and reference lists, so the claim attributed to this source cannot be checked against our copy; no passage contradicts it either, and no alternative source for the ketamine point is named in our copy. (LLM, conf=0.80)
- Could not verifycites [44] Schifano F, Chiappini S. Pregabalin: A range of misuse-related unanswered questions. CNS Neurosci Ther. 2019 May;25(5):659-660. sourceExperimental — accuracy not yet measured
Our copy of Schifano & Chiappini (2019) is entirely about pregabalin/gabapentinoid misuse; no passage mentions ketamine, its receptor actions, or its psychoactive/addictive liability (searched: 'ketamine', 'psychoactive effects addictive liability dissociative NMDA'). The closest passages (Introduction/body, pp. 1-2) discuss pregabalin's action at α2δ-subunit-containing voltage-dependent calcium channels, its GABA-mimetic 'liking' effects, and rat conditioned place preference restricting 'a substantial addictive power' — a different substance, so they neither support nor contradict the ketamine claim. Since the cited paper does not address the point at all, and names no alternative source for a ketamine claim, the verdict is unverifiable rather than disputed or misattributed. (LLM, conf=0.75)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Could not verify
35 more claims · 15 with their cited sources checked
Create a free account to see all 68 claims and to verify the 47 references still open.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The oppositional model of tolerance is also consistent with the use of psychotropic medications as recreational drugs.80”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [80]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Coming off prescribed psychotropic medications: insights from their use as recreational drugs > Recreational and prescribing psychotropics; terminology issues
“In 1968, Di Mascio and Shader (22) specifically addressed the behavioural toxicity of psychotropics.”
§ Coming off prescribed psychotropic medications: insights from their use as recreational drugs > References
“21. Di Mascio A, Shader RI. Behavioral toxicity of psychotropic drugs. I. Definition. II. Toxic effects on psychomotor functions. Conn Med. 1968 Aug;32(8):617-20.”
Citations
Cites
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
Self-citationAntidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
DI CHIARA, G., TANDA, G., BASSAREO, V., PONTIERI, F., ACQUAS, E., FENU, S., CADONI, C., & CARBONI, E. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb09283.x · Cited by 242
The clinical and forensic toxicology of Z-drugs
Gunja, N. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0292-0 · Cited by 230
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Victorri‐Vigneau, C., Dailly, E., Veyrac, G., & Jolliet, P. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02861.x · Cited by 201
Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz007 · Cited by 194
Self-citationMesolimbic dopaminergic decline after cannabinoid withdrawal
Diana, M., Melis, M., Muntoni, A. L., & Gessa, G. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.10269 · Cited by 192
Chiappini, S., & Schifano, F. (2016) · CNS Drugs · doi:10.1007/s40263-016-0359-y · Cited by 189
Self-citationSchifano, F., D’Offizi, S., Piccione, M., Corazza, O., Deluca, P., Davey, Z., Di Melchiorre, G., Di Furia, L., Farré, M., Flesland, L., et al. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000321079 · Cited by 187
Self-citationFrom “Special K” to “Special M”: The Evolution of the Recreational Use of Ketamine and Methoxetamine
Corazza, O., Assi, S., & Schifano, F. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12063 · Cited by 146
Self-citationCraving in Opioid Use Disorder: From Neurobiology to Clinical Practice
Kakko, J., Alho, H., Baldacchino, A., Molina, R., Nava, F. A., & Shaya, G. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00592 · Cited by 140
A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders
Wilkinson, S. T., Toprak, M., Turner, M. S., Levine, S. P., Katz, R. B., & Sanacora, G. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17020239 · Cited by 125
New/emerging psychoactive substances and associated psychopathological consequences
Schifano, F., Napoletano, F., Chiappini, S., Guirguis, A., Corkery, J. M., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. (2021) · Psychological Medicine · doi:10.1017/s0033291719001727 · Cited by 119
Self-citationMarsden, J., White, M., Annand, F., Burkinshaw, P., Carville, S., Eastwood, B., Kelleher, M., Knight, J., O'Connor, R., Tran, A., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30331-1 · Cited by 106
Nielsen, M., Hansen, E. H., & Gøtzsche, P. C. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03686.x · Cited by 103
Corkery, J. M., Loi, B., Claridge, H., Goodair, C., Corazza, O., Elliott, S., & Schifano, F. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.012 · Cited by 98
Self-citationSchifano, F., Chiappini, S., Corkery, J., & Guirguis, A. (2018) · Brain Sciences · doi:10.3390/brainsci8040073 · Cited by 93
Self-citationIatrogenic Factors in Psychopathology
Fava, G. A., & Rafanelli, C. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000500151 · Cited by 82
‘New/Designer Benzodiazepines’: An Analysis of the Literature and Psychonauts’ Trip Reports
Orsolini, L., Corkery, J. M., Chiappini, S., Guirguis, A., Vento, A., De Berardis, D., Papanti, D., & Schifano, F. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200110121333 · Cited by 82
Self-citationThe clinical challenges of synthetic cathinones
Schifano, F., Napoletano, F., Arillotta, D., Zangani, C., Gilgar, L., Guirguis, A., Corkery, J. M., & Vento, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14132 · Cited by 73
Self-citationOrsolini, L., Francesconi, G., Papanti, D., Giorgetti, A., & Schifano, F. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2466 · Cited by 70
Self-citationMDMA (“ecstasy”) abuse: Psychopathological features and craving for chocolate: A case series
Schifano, F., & Magni, G. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90088-4 · Cited by 58
Self-citationWeikop, P., Kehr, J., & Scheel-Krüger, J. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800311 · Cited by 57
Behavioral Toxicity Revisited: Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment
Fava, G. A., Cosci, F., Offidani, E., & Guidi, J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000570 · Cited by 55
Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00046 · Cited by 55
Self-citationEffects of Treatment Discontinuation in Clinical Psychopharmacology
Baldessarini, R. J., & Tondo, L. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000497334 · Cited by 52
Felicetti, P., Trotta, F., Bonetto, C., Santuccio, C., Brauchli Pernus, Y., Burgner, D., Chandler, R., Girolomoni, G., Hadden, R. D. M., Kochhar, S., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2015.09.027 · Cited by 50
Carrus, D., & Schifano, F. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318272864d · Cited by 49
Self-citationAddiction theory matters—Why there is no dependence on caffeine or antidepressant medication
Heinz, A., Daedelow, L. S., Wackerhagen, C., & Di Chiara, G. (2020) · Addiction Biology · doi:10.1111/adb.12735 · Cited by 45
Chiappini, S., & Schifano, F. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000814 · Cited by 44
Self-citationSchifano, F., & Chiappini, S. (2018) · PLOS ONE · doi:10.1371/journal.pone.0204443 · Cited by 44
Self-citationValeriani, G., Corazza, O., Bersani, F. S., Melcore, C., Metastasio, A., Bersani, G., & Schifano, F. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2431 · Cited by 41
Self-citationAddictive Potential of Quetiapine
MURPHY, D., BAILEY, K., STONE, M., & WIRSHING, W. C. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020277 · Cited by 39
Is There a Potential of Misuse for Venlafaxine and Bupropion?
Schifano, F., & Chiappini, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00239 · Cited by 38
Self-citationLyphout, C., Yates, C., Margolin, Z. R., Dargan, P. I., Dines, A. M., Heyerdahl, F., Hovda, K. E., Giraudon, I., Bucher‐Bartelson, B., Green, J., et al. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2550-1 · Cited by 37
Novel Opioids: Systematic Web Crawling Within the e-Psychonauts’ Scenario
Arillotta, D., Schifano, F., Napoletano, F., Zangani, C., Gilgar, L., Guirguis, A., Corkery, J. M., Aguglia, E., & Vento, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00149 · Cited by 37
Self-citationPregabalin: A range of misuse‐related unanswered questions
Schifano, F., & Chiappini, S. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13115 · Cited by 36
Self-citationInternational Task Force on Benzodiazepines
Balon, R., Chouinard, G., Cosci, F., Dubovsky, S. L., Fava, G. A., Freire, R. C., Greenblatt, D. J., Krystal, J. H., Nardi, A. E., Rickels, K., et al. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000489538 · Cited by 35
Chiappini, S., Schifano, F., Corkery, J. M., & Guirguis, A. (2020) · Brain Sciences · doi:10.3390/brainsci10020105 · Cited by 33
Self-citationBupropion Insufflation in a Teenager
Khurshid, K. A., & Decker, D. H. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454604773840634 · Cited by 29
Clinical staging of ketamine-associated urinary dysfunction: a strategy for assessment and treatment
Wu, P., Wang, Q., Huang, Z., Wang, J., Wu, Q., & Lin, T. (2016) · World Journal of Urology · doi:10.1007/s00345-016-1759-9 · Cited by 28
Orsolini, L., St John-Smith, P., McQueen, D., Papanti, D., Corkery, J., & Schifano, F. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666161111114838 · Cited by 28
Self-citationFrancesconi, G., Orsolini, L., Papanti, D., Corkery, J. M., & Schifano, F. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2476 · Cited by 22
Self-citationVenlafaxine dependence in a patient with a history of alcohol and amineptine misuse
Quaglio, G., Schifano, F., & Lugoboni, F. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02266.x · Cited by 21
Self-citationThe consequences of drug misuse on post-marketing surveillance
Schifano, F., Papanti, G. D., Orsolini, L., & Corkery, J. M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1178571 · Cited by 21
Self-citationParadoxical reaction to benzodiazepines in elderly – Case series
Reddy, M. S. S., Achary, U., Harbishettar, V., Sivakumar, P. T., & Varghese, M. (2018) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2018.04.037 · Cited by 18
Non-medical use of olanzapine by people on methadone treatment
James, P. D., Fida, A. S., Konovalov, P., & Smyth, B. P. (2016) · BJPsych Bulletin · doi:10.1192/pb.bp.115.052886 · Cited by 12
Palmer, R. H. C., Brick, L. A. D., Chou, Y., Agrawal, A., McGeary, J. E., Heath, A. C., Bierut, L. J., Keller, M. C., Johnson, E. O., Hartz, S. M., et al. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.12.034 · Cited by 12
New/emerging psychoactive substances and associated psychopathological consequences – Corrigendum
Schifano, F., Napoletano, F., Chiappini, S., Guirguis, A., Corkery, J., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. E. (2019) · Psychological Medicine · doi:10.1017/s003329171900254x · Cited by 12
Self-citationMotivational drive and alprazolam misuse: A recipe for aggression?
Albrecht, B., Staiger, P. K., Hall, K., Kambouropoulos, N., & Best, D. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.04.040 · Cited by 10
An Insight into Gabapentin and Pregabalin in Scottish Prisoners
Deeb, S., Wylie, F. M., Torrance, H. J., & Scott, K. S. (2019) · Journal of Analytical Toxicology · doi:10.1093/jat/bkz105 · Cited by 10
Benzodiazepines, antidepressants and addiction: A plea for conceptual rigor and consistency
Balon, R., Silberman, E. K., Starcevic, V., Cosci, F., Freire, R. C., Nardi, A. E., Rickels, K., & Shader, R. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119878171 · Cited by 7
Franc, A., Kubová, K., Elbl, J., Muselík, J., Vetchý, D., Šaloun, J., & Opatřilová, R. (2019) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2016-001163 · Cited by 5
Research works printed but not linked: 8
- Taylor S, Annand F, Burkinshaw P, Greaves F, Kelleher M, Knight J, Perkins C, Tran A, White M, Marsden J. Dependence and withdrawal associated with some prescribed medicines: an evidence review. Public Health England, London. 2019.
- Buhagiar K, Ghafouri M, Dey M. Oral antipsychotic prescribing and association with neighbourhood-level socioeconomic status: analysis of time trend of routine primary care data in England, 2011-2016. Soc Psychiatry Psychiatr Epidemiol. Feb;55(2):165-173
- American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, 2013
- Di Mascio A, Shader RI. Behavioral toxicity of psychotropic drugs. I. Definition. II. Toxic effects on psychomotor functions. Conn Med. 1968 Aug;32(8):617-20.
- Vento AE, Schifano F, Gentili F, Pompei F, Corkery JM, Kotzalidis GD, et al. Bupropion perceived as a stimulant by two patients with a previous history of cocaine misuse. Ann Ist Super Sanita. 2013;49(4):402-5.
- Michel L, Lang JP. Benzodiazepines and forensic aspects. Encephale. 2003 Nov-Dec;29(6):479-85.
- Schifano F, Papanti GD, Orsolini L, Corkery JM. The consequences of drug misuse on post-marketing surveillance. Expert Rev Clin Pharmacol. 2016 Jul;9(7):867-71
- Pierre JM. Abuse of psychiatric medications: Not just stimulants and benzodiazepines. Curr Psychiatry. Jan;18(1):10-16,
Cited by
Alvarado, R. (2023) · Science and Engineering Ethics · doi:10.1007/s11948-023-00451-3 · Cited by 137
Fava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
Chiappini, S., Vickers-Smith, R., Harris, D., Papanti Pelletier, G. D., Corkery, J. M., Guirguis, A., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Pharmaceuticals · doi:10.3390/ph16070994 · Cited by 78
Self-citationWhat about “Pharming”? Issues Regarding the Misuse of Prescription and Over-the-Counter Drugs
Chiappini, S., & Schifano, F. (2020) · Brain Sciences · doi:10.3390/brainsci10100736 · Cited by 78
Self-citationChiappini, S., Schifano, F., Corkery, J., & Guirguis, A. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959615 · Cited by 47
Self-citation
Metadata
- Authors
- Schifano, F.
- Affiliations
- University of Hertfordshire (GB)
- Corresponding author
- Schifano, Fabrizio
- ORCID
- Schifano, Fabrizio
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2020
- Volume
- 89
- Issue
- 5
- Pages
- 274-282
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W3039134301
- Cited by
- 18
- References
- 56
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 3 · 2022: 3 · 2021: 7 · 2020: 2
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- recreational drug use, prescription drug misuse, substance use disorders, antidepressants, antipsychotic drugs, benzodiazepines
- MeSH terms
- Humans, Psychotropic Drugs, Illicit Drugs, Substance Withdrawal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.